Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07796516 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis

Name: Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis — clinical trial record (NCT07796516)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorPeking University People's Hospital

Started2026-09-01

View on ClinicalTrials.gov ↗

Peking University People's Hospital

220 trials monitored

See 6 trials at risk

Rheumatoid Arthritis

612 trials monitored

See 11 trials at risk

This study is a multicenter, open-label, randomized controlled trial designed to preliminarily evaluate the efficacy and safety of telitacicept in patients with refractory rheumatoid arthritis during a 24-week treatment period followed by a 2-week follow-up period.

Trial Details

NCT Number	NCT07796516
Lead Sponsor	Peking University People's Hospital
Conditions	Difficult-to-treat Rheumatoid Arthritis, Rheumatoid Arthritis
Enrollment	420 participants
Start Date	2026-09-01
Primary Completion	2027-12-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-01